Fortrea appointed Tracy Krumme as senior vice president of investor relations, succeeding Hima Inguva.
Quiver AI Summary
Fortrea, a global contract research organization (CRO), has appointed Tracy Krumme as senior vice president of investor relations, taking over from Hima Inguva, who has decided to pursue other opportunities. Krumme, who has over three decades of experience in investor relations and capital markets, will report to CFO Jill McConnell and will be responsible for Fortrea’s global investor relations strategy. McConnell praised Krumme for her expertise in the field, particularly in the CRO and life sciences sectors. Krumme previously held investor relations roles at companies like PPD and Bitfarms, and she expressed excitement about joining Fortrea at a crucial time as it develops its vision and value proposition for shareholders. Fortrea specializes in providing clinical development solutions for the life sciences industry, supporting pharmaceutical and biopharmaceutical companies in bringing innovative therapies to market.
Potential Positives
- The appointment of Tracy Krumme as senior vice president, investor relations, indicates a strategic move to strengthen investor relations as the company evolves into an independent CRO.
- Krumme brings over three decades of relevant experience in investor relations and capital markets, which can enhance Fortrea’s communications with the investment community.
- The leadership transition signifies continuity and potential stability in investor relations strategies, given Hima Inguva’s long tenure and contributions since the company's founding.
- Krumme's previous success in leading investor relations at notable companies signals potential for Fortrea to improve its market presence and strategic growth initiatives.
Potential Negatives
- The departure of Hima Inguva, a founding member and former head of investor relations, may raise concerns among investors regarding continuity and the company's strategic direction.
- The announcement of a new senior vice president for investor relations suggests a distraction within the company as it undergoes leadership changes during a critical period of growth.
- Tracy Krumme's previous role at Bitfarms, a company in the energy sector, could lead to apprehension regarding her familiarity with the CRO industry, potentially impacting investor confidence.
FAQ
Who has been appointed as Fortrea's new senior vice president of investor relations?
Tracy Krumme has been appointed as the new senior vice president of investor relations at Fortrea.
What experience does Tracy Krumme bring to Fortrea?
Krumme brings over 30 years of investor relations and capital markets experience, particularly in the CRO and life sciences sectors.
What role will Tracy Krumme serve at Fortrea?
Krumme will lead Fortrea’s global investor relations strategy and act as a liaison to the investment community.
Who did Tracy Krumme succeed in her role?
Krumme succeeded Hima Inguva, who has decided to pursue other career opportunities.
What is Fortrea's primary focus as a company?
Fortrea is a leading global provider of clinical development solutions, focusing on accelerating healthcare innovation and delivering therapies to patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FTRE Congressional Stock Trading
Members of Congress have traded $FTRE stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FTRE stock by members of Congress over the last 6 months:
- REPRESENTATIVE J. FRENCH HILL sold up to $15,000 on 06/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$FTRE Insider Trading Activity
$FTRE insiders have traded $FTRE stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $FTRE stock by insiders over the last 6 months:
- JILL G. MCCONNELL (Chief Financial Officer) has made 0 purchases and 5 sales selling 6,101 shares for an estimated $47,682.
- MARK A. MORAIS (Chief Operating Officer) has made 0 purchases and 5 sales selling 6,033 shares for an estimated $47,400.
- JAMES S. HANSON (General Counsel) has made 0 purchases and 2 sales selling 3,198 shares for an estimated $18,904.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FTRE Hedge Fund Activity
We have seen 176 institutional investors add shares of $FTRE stock to their portfolio, and 176 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 4,913,949 shares (-81.2%) from their portfolio in Q1 2025, for an estimated $37,100,314
- MORGAN STANLEY added 4,370,497 shares (+418.4%) to their portfolio in Q1 2025, for an estimated $32,997,252
- MILLENNIUM MANAGEMENT LLC added 2,881,461 shares (+466.4%) to their portfolio in Q1 2025, for an estimated $21,755,030
- FMR LLC removed 2,834,166 shares (-35.0%) from their portfolio in Q1 2025, for an estimated $21,397,953
- BECK MACK & OLIVER LLC removed 2,700,885 shares (-47.9%) from their portfolio in Q1 2025, for an estimated $20,391,681
- STARBOARD VALUE LP removed 2,210,000 shares (-29.6%) from their portfolio in Q1 2025, for an estimated $16,685,500
- SESSA CAPITAL IM, L.P. removed 1,964,494 shares (-29.5%) from their portfolio in Q1 2025, for an estimated $14,831,929
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FTRE Analyst Ratings
Wall Street analysts have issued reports on $FTRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 08/04/2025
- Barclays issued a "Underweight" rating on 05/13/2025
To track analyst ratings and price targets for $FTRE, check out Quiver Quantitative's $FTRE forecast page.
$FTRE Price Targets
Multiple analysts have issued price targets for $FTRE recently. We have seen 5 analysts offer price targets for $FTRE in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Eric Coldwell from Baird set a target price of $9.0 on 08/04/2025
- Ann Hynes from Mizuho set a target price of $7.0 on 07/11/2025
- Elizabeth Anderson from Evercore ISI Group set a target price of $5.0 on 07/09/2025
- Matthew Sykes from Goldman Sachs set a target price of $5.0 on 05/14/2025
- Luke Sergott from Barclays set a target price of $5.0 on 05/13/2025
Full Release
DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea’s global investor relations strategy, serving as a key liaison to the investment community.
“Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter,” said McConnell. “She brings not only deep capital markets expertise but also integrity, insight and a strong track record of supporting strategic transformation and growth. We’re excited to welcome her to the team. I also would like to express my sincere appreciation to Hima Inguva, who has led Fortrea’s Investor Relations since our founding as a company. We wish her every success in her next chapter.”
Krumme brings more than three decades of investor relations and capital markets experience to Fortrea, with expertise across the CRO, life sciences and healthcare sectors. She previously served as head of investor relations at PPD, a leading CRO acquired by Thermo Fisher Scientific, where she worked alongside Fortrea’s CEO Anshul Thakral; Galderma, a global dermatology company; and Nuance Communications, a provider of healthcare AI solutions acquired by Microsoft. Most recently, she was senior vice president, head of investor relations and corporate communications at Bitfarms, a global energy and compute infrastructure company. Earlier in her career, she led investor relations at Luxoft, acquired by DXC Technology, and NCR Corporation, and held roles as an equity research analyst at Sandler O’Neill & Partners and in corporate finance at Prudential Securities and Kidder, Peabody International in London.
“I’m excited to join Fortrea at such a pivotal moment in its evolution as an independent, pure-play CRO,” said Krumme. “I look forward to working with the leadership team to articulate Fortrea’s vision and value proposition to the investment community as we deliver differentiated solutions to our customers and generate long-term value for shareholders.”
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707,
[email protected]
Hima Inguva (Investors) – 877-495-0816,
[email protected]
Sue Zaranek (Media) – 919-943-5422,
[email protected]
Kate Dillon (Media) – 646-818-9115,
[email protected]
